Published in Biol Chem on October 01, 2014
LC-MS/MS quantitation of esophagus disease blood serum glycoproteins by enrichment with hydrazide chemistry and lectin affinity chromatography. J Proteome Res (2014) 0.82
C-Terminal Alpha-1 Antitrypsin Peptide: A New Sepsis Biomarker with Immunomodulatory Function. Mediators Inflamm (2016) 0.78
Identification of Potential Biomarkers for Rhegmatogenous Retinal Detachment Associated with Choroidal Detachment by Vitreous iTRAQ-Based Proteomic Profiling. Int J Mol Sci (2016) 0.75
Therapeutic Benefits of Induced Pluripotent Stem Cells in Monocrotaline-Induced Pulmonary Arterial Hypertension. PLoS One (2016) 0.75
α-Linoleic acid enhances the capacity of α-1 antitrypsin to inhibit lipopolysaccharide-induced IL-1β in human blood neutrophils. Mol Med (2016) 0.75
Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease. Ann Am Thorac Soc (2016) 0.75
Transglutaminase binding fusion protein linked to SLPI reduced corneal inflammation and neovascularization. BMC Ophthalmol (2015) 0.75
Exploration of α1-antitrypsin treatment protocol for islet transplantation: dosing plan and route of administration. J Pharmacol Exp Ther (2016) 0.75
Hepatic steatosis depresses alpha-1-antitrypsin levels in human and rat acute pancreatitis. Sci Rep (2015) 0.75
Implications of the three-dimensional structure of alpha 1-antitrypsin for structure and function of serpins. Biochemistry (1989) 3.18
Alpha 1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J Clin Invest (1990) 2.35
Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice. Proc Natl Acad Sci U S A (2008) 1.83
alpha-1 antitrypsin inhibits caspase-3 activity, preventing lung endothelial cell apoptosis. Am J Pathol (2006) 1.81
Alpha1-antitrypsin monotherapy prolongs islet allograft survival in mice. Proc Natl Acad Sci U S A (2005) 1.61
Alpha1-antitrypsin protects beta-cells from apoptosis. Diabetes (2007) 1.55
alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice. Proc Natl Acad Sci U S A (2008) 1.53
Alpha-1-antitrypsin and a broad spectrum metalloprotease inhibitor, RS113456, have similar acute anti-inflammatory effects. Lab Invest (2001) 1.43
Alpha1-antitrypsin gene therapy modulates cellular immunity and efficiently prevents type 1 diabetes in nonobese diabetic mice. Hum Gene Ther (2006) 1.41
Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med (1993) 1.39
α-1 Antitrypsin regulates human neutrophil chemotaxis induced by soluble immune complexes and IL-8. J Clin Invest (2010) 1.38
Alpha-1-antitrypsin is an endogenous inhibitor of proinflammatory cytokine production in whole blood. J Leukoc Biol (2009) 1.37
Functional protection by acute phase proteins alpha(1)-acid glycoprotein and alpha(1)-antitrypsin against ischemia/reperfusion injury by preventing apoptosis and inflammation. Circulation (2000) 1.30
The discovery of α1-antitrypsin and its role in health and disease. Respir Med (2011) 1.30
Role of protease-activated receptors in inflammatory responses, innate and adaptive immunity. J Leukoc Biol (2008) 1.28
Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation. J Mol Biol (1998) 1.26
Alpha1-antitrypsin, old dog, new tricks. Alpha1-antitrypsin exerts in vitro anti-inflammatory activity in human monocytes by elevating cAMP. J Biol Chem (2007) 1.16
alpha1-Antitrypsin inhibits the lethal response to TNF in mice. J Immunol (1996) 1.16
Recombinant adeno-associated virus-mediated alpha-1 antitrypsin gene therapy prevents type I diabetes in NOD mice. Gene Ther (2004) 1.14
Alpha-1-antitrypsin monotherapy reduces graft-versus-host disease after experimental allogeneic bone marrow transplantation. Proc Natl Acad Sci U S A (2011) 1.13
Expanding the clinical indications for α(1)-antitrypsin therapy. Mol Med (2012) 1.10
Inhibition of neutrophil superoxide production by human plasma alpha 1-antitrypsin. FEBS Lett (1992) 1.10
Inhibition of lipopolysaccharide-mediated human monocyte activation, in vitro, by alpha1-antitrypsin. Biochem Biophys Res Commun (2004) 1.04
α-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol (2012) 1.04
Prolastin, a pharmaceutical preparation of purified human alpha1-antitrypsin, blocks endotoxin-mediated cytokine release. Respir Res (2005) 1.01
Alpha 1-acid glycoprotein and alpha 1-antitrypsin inhibit TNF-induced but not anti-Fas-induced apoptosis of hepatocytes in mice. J Immunol (1997) 1.00
alpha 1-Proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglobulin are the antiapoptotic factors of vascular smooth muscle cells. J Biol Chem (2000) 0.99
Alpha 1-antitrypsin reduces inflammation and enhances mouse pancreatic islet transplant survival. Proc Natl Acad Sci U S A (2012) 0.98
Intradermal alpha1-antitrypsin therapy avoids fatal anaphylaxis, prevents type 1 diabetes and reverses hyperglycaemia in the NOD mouse model of the disease. Diabetologia (2010) 0.97
The circulating proteinase inhibitor α-1 antitrypsin regulates neutrophil degranulation and autoimmunity. Sci Transl Med (2014) 0.97
α 1-antitrypsin enhances insulin secretion and prevents cytokine-mediated apoptosis in pancreatic β-cells. Islets (2010) 0.97
Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model. Blood (2011) 0.97
Sustained expression of circulating human alpha-1 antitrypsin reduces inflammation, increases CD4+FoxP3+ Treg cell population and prevents signs of experimental autoimmune encephalomyelitis in mice. Metab Brain Dis (2011) 0.95
alpha1-Antitrypsin regulates CD14 expression and soluble CD14 levels in human monocytes in vitro. Int J Biochem Cell Biol (2007) 0.94
Alpha-1 antitrypsin protein and gene therapies decrease autoimmunity and delay arthritis development in mouse model. J Transl Med (2011) 0.89
Alpha 1-antitrypsin binds to and interferes with functionality of EspB from atypical and typical enteropathogenic Escherichia coli strains. Infect Immun (2004) 0.88
Divergent effects of alpha1-antitrypsin on neutrophil activation, in vitro. Biochem Biophys Res Commun (2004) 0.86
Antiproteinases protect cultured lung endothelial cells from endotoxin injury. J Appl Physiol (1985) (1988) 0.85
Aggrecanase-1 (ADAMTS-4) interacts with alpha1-antitrypsin. Biochim Biophys Acta (2005) 0.83
Saving islets from allograft rejection. Proc Natl Acad Sci U S A (2005) 0.83
C-36 peptide, a degradation product of alpha1-antitrypsin, modulates human monocyte activation through LPS signaling pathways. Int J Biochem Cell Biol (2005) 0.83
Endotoxin receptor CD14 in PiZ alpha-1-antitrypsin deficiency individuals. Respir Res (2008) 0.81
Immune-directed therapy for type 1 diabetes at the clinical level: the Immune Tolerance Network (ITN) experience. Rev Diabet Stud (2012) 0.79
Human α1-antitrypsin modifies B-lymphocyte responses during allograft transplantation. Immunology (2013) 0.78
Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes (2012) 2.02
Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest (2015) 1.19
Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides (2003) 1.14
Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech (2014) 0.92
Immune interventions to preserve β cell function in type 1 diabetes. J Investig Med (2016) 0.80
Targeted immune interventions for type 1 diabetes: not as easy as it looks! Curr Opin Endocrinol Diabetes Obes (2014) 0.77
Safety issues associated with the use of angiotensin-converting enzyme inhibitors. Expert Opin Drug Saf (2006) 0.76
Antifibrotic peptide N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP): opportunities for angiotensin-converting enzyme inhibitor design. Clin Exp Pharmacol Physiol (2013) 0.75
Anti-Gal and anti-Neu5Gc responses in nonimmunosuppressed patients following treatment with rabbit anti-thymocyte polyclonal IgGs. Transplantation (2017) 0.75